What is DAWN's current stock price?

DAWN (Day One Biopharmaceuticals, Inc.) is currently trading at $21.53 with a market cap of $2.22B.

What sector is Day One Biopharmaceuticals, Inc. in?

Day One Biopharmaceuticals, Inc. (DAWN) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is DAWN a good stock to buy?

Analysts have a Hold consensus on DAWN with a price target of $21.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

DAWN Day One Biopharmaceuticals, Inc.

Healthcare

$21.53+0.00%OpenMarket Cap: $2.22B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.05

P/S

14.06

EV/EBITDA

-16.38

DCF Value

$55.67

FCF Yield

-4.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

89.1%

Operating Margin

-80.8%

Net Margin

-67.8%

ROE

-23.4%

ROA

-21.1%

ROIC

-28.0%

Financials

View All

Period	Revenue	Net Income	EPS
Q4 null	$53.7M	$-21.3M	$—
FY null	$158.2M	$-107.3M	$—
Q3 null	$39.8M	$-19.7M	$—
Q2 null	$33.9M	$-30.3M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$21.50

Target (Median)

$21.50

Target Range

$21.50 - $21.50

0 Strong Buy0 Buy8 Hold0 Sell0 Strong Sell

JP MorganNeutral

2026-03-11

HC Wainwright & Co.Neutral

2026-03-10

WedbushNeutral

2026-03-09

Jones TradingHold

2026-03-06

NeedhamHold

2026-03-06

Trading Activity

Insider Trades

View All

AI Day1 LLC10 percent owner

SellMon Apr 27

AI Day1 LLC10 percent owner

SellMon Apr 27

York Charles N IIofficer: COO and CFO

SellThu Apr 23

York Charles N IIofficer: COO and CFO

SellThu Apr 23

VASCONCELLES MICHAELofficer: Head of Research and Dev.

SellThu Apr 23

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-1.75

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Peers